A Mechanistic Study to Evaluate the Vasodilatory Effects of AZD3427 in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) and Patients with Heart Failure with Reduced Ejection Fraction (HFrEF)
18 Years - 75 Years
Endpoint Classification: -
Intervention Model: Single Group Assignment
Primary Purpose: Treatment
Verified 01 Oct 2021 by AstraZeneca
No locations available
|Experimental: Patients with HFpEF or HFrEF|
Patients will be enrolled in 2 cohorts in parallel: 1 cohort of patients with HFpEF and 1 cohort of patients with HFrEF. Patients will receive a sequence of 5 IA infusions into the brachial artery, consisting of a baseline saline infusion of approximately 20 minutes, followed by 3 sequential infusions of AZD3427 at ascending doses of approximately 10 minutes (each) and a washout saline infusion of approximately 15 minutes.
Patients will receive 5 IA infusions of AZD3427 into the brachial artery. The IA infusions of AZD3427 will be administered via a syringe pump, using a polypropylene syringe containing 0.9% (w/v) saline and delivered through an administration set comprising a syringe, extension tubing (PVC), and a 0.2- or 0.22-μm PVDF syringe filter.